TY - JOUR T1 - Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials JF - medRxiv DO - 10.1101/2021.07.16.21260509 SP - 2021.07.16.21260509 AU - Reshma Ramachandran AU - Joseph S. Ross AU - Jennifer E. Miller Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/22/2021.07.16.21260509.abstract N2 - The COVID-19 pandemic has led to the rapid development of multiple vaccines, vaccines that were tested in clinical trials located in several countries around the world. Because prior research has shown that pharmaceuticals do not receive consistent and timely authorization for use in lower-income countries where they are tested, we conducted a cross-sectional study examining the authorization or approval and delivery for COVID-19 vaccines recommended by the World Health Organization (WHO) in the countries where they were tested. While countries of varying incomes have largely authorized the COVID-19 vaccines tested within their populations for use, high-income countries have received proportionately more doses, enabling them to more fully vaccinate their populations. As many lower-income countries continue to experience inequitable shortfalls in COVID-19 vaccine supply amid the ongoing pandemic, efforts must be undertaken to ensure timely access in countries across all income groups, including those hosting clinical trials.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: RR is a board member for Universities Allied for Essential Medicines North America, which is a member organization in The Peoples Vaccine coalition and also co-hosts the Free the Vaccine campaign. While RR is an employee of the Veterans Health Administration, the views expressed in this article are those of the authors and do not necessarily reflect those of the U.S. Department of Veteran Affairs or the U.S. government. In the past 36 months, JSR formerly received research support through Yale University from the Laura and John Arnold Foundation for the Collaboration for Research Integrity and Transparency (CRIT) at Yale; JSR currently receives support from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); JSR received research support through Yale University from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585) and from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I); JSR currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International. JEM reports receiving grants from Arnold Ventures, Susan G. Komen Foundation, and the National Institutes of Health (NOT-OD-20-121) during the conduct of this study as well as serving on advisory committees for Alexion and Cambia Health and the board of directors for Bioethics International.Funding StatementThis project was not supported by any external grants or funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As no human subjects were involved, this study did not require ethics approval or patient consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDr. Ramachandran had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Requests for the dataset can be made to the corresponding author at reshma.ramachandran{at}yale.edu. ER -